− Hypersensitivity to thalidomide or to any of the excipients. − Pregnant women (see section 4.6). − Women of childbearing potential unless all the conditions of the Thalidomide Celgene Pregnancy Prevention Programme are met (see sections 4.4 and 4.6). − Patients unable to follow or comply with the required contraceptive measures (see section 4.4).